王志杰教授:HER2 ADC改变HER2变异晚期NSCLC患者治疗格局 人表皮生长因子受体2(HER2)基因变异是非小细胞肺癌(NSCLC)中常见的基因异常之一,随着精准治疗的日益发展,HER2变异患者的诊疗愈发引起临床的关注。既往针对HER2变异NSCLC的治疗方案比较有限,化疗、小分...
3. Shafi H, Astvatsaturyan K, Chung F et al. Clinicopathological significance ofHER2/neu genetic heterogeneity in HER2/neu non-amplified invasive breast carcinomasand its concurrent axillary metastasis. J Clin Pathol 2013; 66: 649-654. 4. Kurozumi S, ...
3. Shafi H, Astvatsaturyan K, Chung F et al. Clinicopathological significance of HER2/neu genetic heterogeneity in HER2/neu non-amplified invasive breast carcinomas and its concurrent axillary metastasis. J Clin Pathol 2013; 66: 649-654. 4. Kurozumi S, Padilla M, Kurosumi M et al. HER2 ...
后来,科学家发现,neu和早先发现的病毒ERBB2基因的结构相似,是ERBB2在哺乳动物中的“版本”,因此,neu又有了别名ErbB-2。而ERBB2在人类中编码的蛋白又和人表皮生长因子受体结构相似,所以,neu又有了第三个名字--HER2[2]。 在发现了neu之后,Weinberg教授并没有太在意它,当时,他的团队在努力攻坚RAS基因的克隆。这...
27.Canonici,A.et al.Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.Oncotarget 4,1592–1605(2013). 28.Chan,A.et al.Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer(ExteNET):a multicentre,randomised,double-blind,placebo-controlle...
Of 30 cases with gene amplification, 4 (13%) showed a "not-amplified pattern" in other parts of the tumor. The routine assessment of HER2/neu amplification using the ASCO/CAP criteria on whole tissue sections is not significantly confounded by intratumoral heterogeneity in breast cancer with ...
免疫反应因何而来?这位研究员发现,原来,是癌变细胞表面存在由大鼠的基因表达的一种特殊蛋白。因为这个基因来自于大鼠的神经系统肿瘤细胞,因此Weinberg教授将它命名为neu[1]。 后来,科学家发现,neu和早先发现的病毒ERBB2基因的结构相似,是ERBB2在哺乳动物中的“版本”,因此,neu又有了别名ErbB-2。而ERBB2在人类中编码...
27.Canonici,A.et al.Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer.Oncotarget 4,1592–1605(2013). 28.Chan,A.et al.Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer(ExteNET):a multicentre,randomised,double-blind,placebo-controlle...
27. Meric-Bernstam F, Hurwitz H, Raghav KPS, et al. Pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer (MyPathway): an updated report from a multicentre, open-label, phase 2a, multiple basket study. Lancet Oncol. 2019;20(4):518-530. doi:10.1016/S1470-2045(18)3090...
[17].Kris MG, Camidge DR, Giaccone G, et al. Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors. Ann Oncol. 2015;26(7):1421-1427. doi:10.1093/annonc/mdv186...